Join Growin Stock Community!

Aeon biopharma, inc.AEON.US Overview

US StockHealthcare
(No presentation for AEON)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

AEON AI Insights

AEON Overall Performance

AEON AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

AEON Recent Performance

-1.42%

Aeon biopharma, inc.

-3.61%

Avg of Sector

-2.16%

S&P500

AEON PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

AEON Key Information

AEON Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

AEON Profile

AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.

Price of AEON

AEON FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

AEON Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.00
PE Ratio (TTM)
-
Forward PE
1.16
PS Ratio (TTM)
97.16
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.00
PE Ratio (TTM)
-
Forward PE
1.16
PS Ratio (TTM)
97.16
PB Ratio
-
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is AEON's latest earnings report released?

    The most recent financial report for Aeon biopharma, inc. (AEON) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating AEON's short-term business performance and financial health. For the latest updates on AEON's earnings releases, visit this page regularly.

  • How much cash does AEON have?

    At the end of the period, Aeon biopharma, inc. (AEON) held Total Cash and Cash Equivalents of 5.93M, accounting for 0.68 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is AEON's EPS continuing to grow?

    According to the past four quarterly reports, Aeon biopharma, inc. (AEON)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.39. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of AEON?

    Aeon biopharma, inc. (AEON)'s Free Cash Flow (FCF) for the period is -2.6M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 12.15% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of AEON?

    The latest valuation data shows Aeon biopharma, inc. (AEON) has a Price-To-Earnings (PE) ratio of -3,569.69 and a Price/Earnings-To-Growth (PEG) ratio of 0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.